Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Mei Wang China

biotech focusing on world leading r&d to solve unmet medical needs
Website:
www.dizalpharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
dizal pharmaceutical
team leader 

Yuqi Wang China

QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
Website:
www.parkinsons-disease-care.mysxl.cn
Partnering Objectives
Headquartner in China
Yes
QiRun Biotech
Founder 

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality
Business Development

grace wang China

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.
Website:
www.atmbio.com
Partnering Objectives
Headquartner in China
Yes
Beijing ATMbiomaterials Co., Ltd
MD 

Ms Luyao Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Director of PR 
Functionality
Other

Miss Chara Wang China

Big Pharma
Website:
sanofi
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
understand the mkt
Headquartner in China
Yes
Biotech/Pharma Category
Sanofi
FBP 
Functionality
Other

William Wang China

see company website
Website:
www.tiandapharma.com
Partnering Objectives
Headquartner in China
Yes
Tianda Pharmaceutical Ltd.
CEO 

Ying Wang China

Pharma and diagnostics
Website:
Roche.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Roche
BD director 

Mr. Jibo Wang China

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs
Website:
https://www.luye.cn
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
more RA knowledge
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Luye pharma
RA specialist 

Dr. Weiqing Wang China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
AnHeart Therapeutics
Associate Director of BD 
Functionality
Business Development